Practical Neurology

Our 2025 @US_FDA Special Report highlights newly approved therapies, key label updates, and notable device clearances in the field of #neurology. This report brings together the most impactful developments shaping clinical practice. Read now! @AANmember ow.ly/2AcP50Yx2v2

High-dose #Spinraza (#nusinersen) improved functional outcomes and reduced the risk of death or permanent ventilation vs the standard regimen in #SMA. New data from DEVOTE and ONWARD studies presented at #MDA2026. ow.ly/m8Ix50Yvuui @MDAorg @AANmember @GSK #SpinalMuscularAtrophy

Neuroimaging is redefining #Alzheimer's and related #Dementias. From structural MRI ➡️ amyloid & tau PET, biomarkers are moving us toward earlier, more precise diagnosis. Dr. Masdeu (@MethodistHosp) Dr. Ajtai (@DentInstitute), & Dr. Berteleson (@DellMedSchool) provide a must-read clinical guide 👇 ow.ly/J1Sy50YvuM3 #NeuroTwitter #Dementia @AANmember @alzassociation @DENTNeurologic

New data from the MESA open-label extension study—presented at the 2026 #MDAconference—found that individuals with #Becker_muscular_dystrophy treated with a skeletal myosin inhibitor maintained baseline NSAA scores for up to 3.5 y. ow.ly/2JLy50YuXvY @MDAorg #BMD #MuscularDystrophy

Our March issue on #neuroimaging is now live! Medical Editor Laszlo Mechtler, MD (@DentInstitute) brings together leading experts to discuss how #imaging shapes #diagnosis, #localization, and #care, from #MRI to connectivity mapping, #AI-enabled interpretation, & more. Read our new issue today: ow.ly/hqQI50YuYXg @AANmember @asneuroimaging @RSNA

Combination #NeuroBlate and #Keytruda significantly improved median overall and progression-free survival vs non-NeuroBlate surgery and Keytruda for people with recurrent high-grade #astrocytoma. @MonterisMed @Merck ow.ly/FmyO50YtaQ7

The antisense oligonucleotide zorevunersen reduced convulsive seizure frequency by up to 90.91% in children and adolescents with Dravet syndrome, according to results from phase 1/2a trials and extension studies. @NEJM @AmEpilepsySoc #seizures #epilepsy ow.ly/LCxu50YsGw0

May Ling Kopecky is the cover artist for our January/February issue. May uses her artwork to visualize her experiences with #multiple_sclerosis and to advocate for others. ow.ly/FjGV50YrBJa @mssociety @MCAD @ACTRIMS

With the updated #McDonaldCriteria highlighting #MRI #biomarkers, understanding #radiologic differences among #MS, #NMOSD, and #MOGAD is increasingly important. Drs Goodman, Kaewsanit, & Brier outline imaging features that help distinguish these disorders. ow.ly/jlmm50Yqvq1 @mssociety @ACTRIMS @washumedicine @AANmember @MatthewBrier #Multiple_Sclerosis

#Fenebrutinib, an oral BTK inhibitor, reduced annualized relapse rate vs #teriflunomide for people with relapsing #MS in results from #FENhance 1. ow.ly/xMAX50YqvWE @Roche @mssociety @ACTRIMS @mscare @AANmember #Multiple_Sclerosis

Treatment with #delpacibart #etedesiran (#del_desiran), an mAb oligonucleotide conjugate, reduced DMPK mRNA levels and demonstrated improvement in downstream splicing #biomarkers in adults with #myotonic #dystrophy type 1. ow.ly/caOy50Yqv3M @MDAOrg @AANmember #DM1

Distinguishing #MS from #NMOSD and #MOGAD is critical—treatments and outcomes differ. Drs Robertson & Khanna with A. Demers review diagnostic criteria, antibody testing, & key imaging patterns that guide accurate classification. ow.ly/gpF350YpVr0 @USFHealthMed @mssociety @mscare @ACTRIMS @AANmember

#Ischemic #Stroke: @JNJMedTech announced the US launch of the CEREGLIDE 42 and CEREGLIDE 57 aspiration catheters, along with the INNERGLIDE 7 delivery aid. ow.ly/l35m50Ypp6H @JNJNews @American_Heart @EVToday

Paramagnetic rim lesions on susceptibility-sensitive MRI were associated with increased risk of developing clinical #MultipleSclerosis in people with #RIS—data published in @JAMANeuro. ow.ly/hkcL50YoUq3 @mscare @mssociety @AANmember

For adults with ocular #Myasthenia_gravis, treatment with #Vyvgart (#efgartigimod) demonstrated statistically significant improvement in patient-reported ocular symptoms. ow.ly/FW5M50Yokoy @MyastheniaOrg @NANOSTweets @AANmember @argenxglobal

Fever increases the likelihood that a #headache is secondary. An article by Drs. Sreepathi, Schneck, Bellacicco, Grosberg, & Chirch w/ @EmmaKCarlson1 provides a algorithmic framework for distinguishing#infectious, #autoimmune/rheumatologic, #endocrine, & drug-related causes of headache with #fever. ow.ly/wVzT50Ynjgo @uconnhealth @ahsheadache @nhf @amfmigraine @AANmember

Visit ow.ly/GO3450YnirZ for new #CME content in #neurology—#Alzheimer disease, #Limb_Girdle #Muscular_Dystrophy, and more. #NeuroTwitter #MedEd @ReachMD

Canada's Drug Agency (@CDA_AMC) has issued a draft recommendation against public reimbursement of #leqembi for early #Alzheimer's, despite prior conditional approval from Health Canada; stakeholder feedback is open through March 5, 2026. ow.ly/rkbe50YmIYQ @GovCanHealth @EisaiUS @genentech #lecanemab @alzassociation

The 2024 #McDonald_Criteria formally recognize the κ free light chain index as an alternative to #oligoclonal bands in #MS diagnosis. An article by @JeffreyDunnMD reviews the biology, diagnostic accuracy, & clinical implications of this biomarker. ow.ly/vtBn50YmIHs @mssociety @mscare @ACTRIMS @AANmember #multiplesclerosis

#Satralizumab treatment prevented and/or delayed time to #MOGAD relapses in results from the phase 3 METEOROID trial. ow.ly/cMBe50Ym6ho #MS @mssociety @mscare @ACTRIMS @genentech